1 ml of 20 mg Parecoxib is given concurrently with 19 mls of 0.75% ropivacaine

19 ml of Ropivacaine at a concentration of 0.75% is given concurrently with 1 ml of 0.9% saline

Anesthesia; Functional

Anesthesia

1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)

Parecoxib 20 MG/ML

19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline

Ropivacaine

PMC Free article link for Sterne JA et al article on multiple imputation

Hospital Universiti Sains Malaysia (HUSM)

The Efficacy of 20 mg Parecoxib as an Adjunct to 0.75% Ropivacaine in Supraclavicular Brachial Plexus Block for Upper Limb Surgery

A Randomized Two-parallel Group Controlled Trial Comparing the Effects of 20mg Parecoxib as an Adjunct to 0.75% Ropivacaine in Ultrasound-guided Supraclavicular Block for Upper Limb Surgery

Time (measured in minutes) required for a 30% decrease in sensation compared to the contralateral upper limb limb as a reference

Time (measured in minutes) from the injection of interventions until a decrease in motor power to at least grade 3

The time (measured in hours) from the injection of interventions until complete recovery in cold and pain sensation confirmed by alcohol swab and pin prick tests in all respective dermatomes of the brachial plexus (C5-T1)

Time (measured in hours) from the injection of allotted interventions until complete recovery of motor power (grade 1) in all dermatomes supplied by brachial plexus (C5-T1)

The presence of complete sensory block at 30 minutes following institution of allotted intervention

The presence of full motor block at 30 minutes following institution of allotted interventions

All individual participant data (IPD) will be shared with other researchers. These include all primary and secondary outcomes of interest and covariate information which include the clinical and demographic profiles of patients.

Wan Nor Arifin Wan Mansor

Universiti Sains Malaysia

Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated for 12 months

Systemic Sclerosis

Calcinosis

Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated

Oral treprostinil

Stanford University School of Medicine

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Number of participants with treatment-related adverse events following

mean rate of change of calcinosis in radiograph following treatment with oral treprostinil as assessed by a novel radiographic scoring system

The Scleroderma Health Assessment Questionnaire (SHAQ) consists of the mean of 8 scores from 8 sections ranging from 0-3 and 6 visual analogue scales ranging from 0-10. The higher the score, the higher the disability.

Cochin Hand Functional Scale is a 18-questions scale, each question ranges from 0 to 5, total score range 0-90. Higher scores indicates higher disability.

The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The higher the score the less disability.

Mawdsley Calcinosis Questionnaire is an 18-question survey, each question ranges from 0-10. Higher scores indicates higher disability from calcinosis

The Raynaud Condition Score is a single question questionnaire, ranges from 0-10, where 10 indicates more active Raynaud phenomenon.

patient global assessment of calcinosis severity at 1 year versus baseline

physician global assessment of calcinosis severity at 1 year versus baseline

SSc-PAH associated biomarkers following treatment with treprostinil at 1 year compared to baseline

baseline cortical area and cortical porosity measured by HR-pQCT in SSc patients with calcinosis at baseline

isopropyl alcohol/seizures

The Efficacy of 20 mg Parecoxib as an Adjunct to 0.75% Ropivacaine in Supraclavicular Brachial Plexus Block for Upper Limb Surgery

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Самая поўная база дадзеных пра лекавыя травы, падтрыманая навукай